BCL11A, the principal switch factor, which was identified through genomewide association studies, directly represses the fetal globin (γ-globin) gene promoter; this repression silences the ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

The BEAM-101 edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, leading to increased production of non-sickling and ...

Poster Presentation: Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of the Novel Oral Fetal Hemoglobin (HBF) Induer Pociredir in Healthy Adults in a Phase 1 study (PF1170 – Friday, June 13) ...

Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the ...

The BEAM-101 edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, leading to increased production of non-sickling and ...

It does so by suppressing the gene BCL11A, which normally shuts down fetal hemoglobin production after birth. This lets fetal hemoglobin production resume. However, Casgevy and other gene ...